Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pacira BioSciences, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,541 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 6,405 · Balance 26,541 F1: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.42 · Expires 2036-06-10 | Direct | 10,891 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Grant · Acquired 10,891 · Balance 10,891 F2: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F2: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 21:06 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 10,891 | $0.00 Strike: $23.42 | $0.00 |
DisclosureSEC source: 0001628280-26-043003 · wk-form4_1781312816.xml · derivative · entry 2 Froimson Mark · CIK 0001709050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,891 Underlying: Common Stock · 10,891 shares Expires 2036-06-10 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 21:06 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 6,405 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-043003 · wk-form4_1781312816.xml · nonDerivative · entry 1 Froimson Mark · CIK 0001709050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,541 F1 · shares: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 17:43 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 500 | $21.81 | $10,905.00 |
DisclosureSEC source: 0001628280-26-019890 · wk-form4_1773956578.xml · nonDerivative · entry 1 Froimson Mark · CIK 0001709050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,136 Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 16:18 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 11,279 | $0.00 Strike: $24.34 | $0.00 |
DisclosureSEC source: 0001396814-25-000085 · wk-form4_1749845889.xml · derivative · entry 2 Froimson Mark · CIK 0001709050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,279 Underlying: Common Stock · 11,279 shares Expires 2035-06-11 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on June 11, 2026, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 16:18 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 6,163 | $0.00 | $0.00 |
DisclosureSEC source: 0001396814-25-000085 · wk-form4_1749845889.xml · nonDerivative · entry 1 Froimson Mark · CIK 0001709050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,636 F1 · shares: Represents restricted stock units that vest on June 11, 2026, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| August 12, 2024 Filed Aug 12, 2024 20:33 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | PurchaseCommon Stock | 1,400 | $11.58 | $16,212.00 |
DisclosureSEC source: 0001396814-24-000107 · wk-form4_1723509201.xml · nonDerivative · entry 1 Froimson Mark · CIK 0001709050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,473 Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 18:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 12,179 | $0.00 Strike: $28.68 | $0.00 |
DisclosureSEC source: 0001396814-24-000077 · wk-form4_1718316798.xml · derivative · entry 2 Froimson Mark · CIK 0001709050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,179 Underlying: Common Stock · 12,179 shares Expires 2034-06-12 Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 18:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 5,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001396814-24-000077 · wk-form4_1718316798.xml · nonDerivative · entry 1 Froimson Mark · CIK 0001709050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,073 F1 · shares: Represents restricted stock units that vest on June 12, 2025, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 17:30 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 12,925 | $0.00 Strike: $38.74 | $0.00 |
DisclosureSEC source: 0001209191-23-038020 · doc4.xml · derivative · entry 2 Froimson Mark · CIK 0001709050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,925 Underlying: Common Stock · 12,925 shares Expires 2033-06-14 Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 17:30 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 1,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038020 · doc4.xml · nonDerivative · entry 1 Froimson Mark · CIK 0001709050 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,843 F1 · shares: Represents restricted stock units that vest on June 3, 2024, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 19:22 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 8,225 | $0.00 Strike: $59.39 | $0.00 |
DisclosureSEC source: 0001209191-22-035218 · doc4.xml · derivative · entry 2 Froimson Mark · CIK 0001709050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,225 Underlying: Common Stock · 8,225 shares Expires 2032-06-08 Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 19:22 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 1,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035218 · doc4.xml · nonDerivative · entry 1 Froimson Mark · CIK 0001709050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,068 F1 · shares: Represents restricted stock units that vest on June 3, 2023, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| May 09, 2022 Filed May 11, 2022 16:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,000 | $59.37 | $59,370.00 |
DisclosureSEC source: 0001209191-22-028275 · doc4.xml · nonDerivative · entry 1 Froimson Mark · CIK 0001709050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,908 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.36 to $59.41, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 16:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GiftCommon Stock | 400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-070553 · doc4.xml · nonDerivative · entry 1 Froimson Mark · CIK 0001709050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,908 Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 20:32 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 7,626 | $0.00 Strike: $60.96 | $0.00 |
DisclosureSEC source: 0001209191-21-040082 · doc4.xml · derivative · entry 2 Froimson Mark · CIK 0001709050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,626 Underlying: Common Stock · 7,626 shares Expires 2031-06-09 Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 20:32 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 1,066 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040082 · doc4.xml · nonDerivative · entry 1 Froimson Mark · CIK 0001709050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,308 F1 · shares: Represents restricted stock units that vest on June 3, 2022, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 20:01 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 734 | $72.26 | $53,038.84 |
DisclosureSEC source: 0001209191-21-021583 · doc4.xml · nonDerivative · entry 1 Froimson Mark · CIK 0001709050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,242 Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 18:23 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 8,027 | $0.00 Strike: $47.65 | $0.00 |
DisclosureSEC source: 0001209191-20-036036 · doc4.xml · derivative · entry 2 Froimson Mark · CIK 0001709050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,027 Underlying: Common Stock · 8,027 shares Expires 2030-06-09 Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 18:23 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 1,260 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036036 · doc4.xml · nonDerivative · entry 1 Froimson Mark · CIK 0001709050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,976 F1 · shares: Represents restricted stock units that vest on June 3, 2021, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| December 16, 2019 Filed Dec 19, 2019 16:14 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GiftCommon Stock | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-061298 · doc4.xml · nonDerivative · entry 1 Froimson Mark · CIK 0001709050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,716 Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 16:30 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 8,437 | $0.00 Strike: $43.54 | $0.00 |
DisclosureSEC source: 0001209191-19-035074 · doc4.xml · derivative · entry 2 Froimson Mark · CIK 0001709050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,437 Underlying: Common Stock · 8,437 shares Expires 2029-06-05 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on the first anniversary of the grant date, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 16:30 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 4,134 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035074 · doc4.xml · nonDerivative · entry 1 Froimson Mark · CIK 0001709050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,016 F1 · shares: Represents restricted stock units that vest on June 3, 2020, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 19:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 4,693 | $0.00 Strike: $38.35 | $0.00 |
DisclosureSEC source: 0001209191-18-038190 · doc4.xml · derivative · entry 2 Froimson Mark · CIK 0001709050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,693 Underlying: Common Stock · 4,693 shares Expires 2028-06-13 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on the first anniversary of the grant date, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 19:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 782 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038190 · doc4.xml · nonDerivative · entry 1 Froimson Mark · CIK 0001709050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 882 F1 · shares: Represents restricted stock units that vest on June 3, 2019, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| August 08, 2017 Filed Aug 16, 2017 20:43 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | PurchaseCommon Stock | 100 | $37.13 | $3,713.16 |
DisclosureSEC source: 0001209191-17-049323 · doc4.xml · nonDerivative · entry 1 Froimson Mark · CIK 0001709050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 20:12 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 8,144 | $0.00 Strike: $44.20 | $0.00 |
DisclosureSEC source: 0001209191-17-040688 · doc4.xml · derivative · entry 1 Froimson Mark · CIK 0001709050 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,144 Underlying: Common Stock · 8,144 shares Expires 2027-06-14 F1 · derivative.exercise_date: The options vest in 36 equal successive monthly installments over the 36-month period following the date of grant, subject to the reporting person's continued service as a director. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.